[Undermanagement of patients with rheumatism. Know-how too often not utilized].
Bischoff
A
A
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000534:rehabilitation*; D017277:Drug Approval; D005858:Germany; D006801:Humans; D020380:Needs Assessment; D010348:Patient Care Team; D011785:Quality Assurance, Health Care; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab